Preliminary results of a phase II trial on solid tumors of detorubicin, a new anthracyclin.
A phase II trial of detorubicin (DTR) has been conducted on 164 patinets with solid tumors. Regressions greater than or equal to 50% were obtained in 23% of breast carcinoma patients, in 17% of head and neck carcinoma patients and of melanoma patients, and in 6% of ureri cervic carcinoma patients. DTR seems as toxic as adriamycin on bone marrow and the heart and might induce a little less alopecia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; C017218:detorubicin; D003630:Daunorubicin